The present study included five different HCV (genotype-4a)-infected individuals with no history of liver cirrhosis or end stage liver disease. A written informed consent was obtained from each patient prior to enrollment in the study and the ethical committees of Kasr el Ainy, School of Medicine and the National Cancer institute, Cairo University approved the study protocol which conformed to the ethical guidelines of the World Medical Association Declaration of Helsinki. Serum samples were collected from patients admitted to Viral Hepatitis Center. Anti-HCV antibodies were detected in sera by fourth-generation ELISA (ETI-AB-HCVK-4, DiaSorin) and infection was confirmed by HCV RT-PCR. All samples were genotyped with Versant HCV genotype assay (LiPA) 2.0 (Innogenetics, Siemens Healthcare Diagnostics, USA) prior to enrollment in the study.
Versant hcv genotype assay lipa 2
Manufactured by Fujirebio
Sourced in United States, Belgium
The Versant HCV genotype assay (LiPA) 2.0 is a laboratory equipment product developed by Fujirebio. It is used for the determination of hepatitis C virus (HCV) genotypes in human serum or plasma samples.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using versant hcv genotype assay lipa 2
1
HCV Genotype-4a Characterization Protocol
2
Measuring HCV RNA Levels and Resistance
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Plasma HCV RNA levels were measured using the cobas® AmpliPrep/cobas® TaqMan® HCV test (version 2.0, Roche Molecular Diagnostics, Branchburg, NJ, USA) with a lower limit of quantitation of 15 IU/mL. Relapse was defined as HCV RNA >15 IU/mL during follow-up after HCV RNA <15 IU/mL at the end of treatment. Determination of HCV GT was conducted using the Versant HCV genotype assay (LiPA) 2.0 (Innogenetics, Ghent, Belgium) or the Abbott RealTime HCV Genotype II assay (Abbott Molecular Inc., Abbott Park, IL, USA). Resistance analyses were performed using population sequencing with a limit of minority variant detection >20% of the viral population. Nonstructural protein 5A (NS5A) resistance-associated substitutions (RASs) were defined as any polymorphism at amino acid positions 28, 30, 31, and 93.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!